This site is intended for U.S. healthcare professionals.
An oral treatment combination for adults with unresectable or metastatic melanoma with a BRAF V600E/K mutation1,2
This is a descriptive post hoc analysis and should be interpreted in the context of this limitation. No conclusions regarding efficacy may be drawn.
Stable disease is not a component of ORR and can reflect the natural progression of disease rather than a direct therapeutic effect.
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) are kinase inhibitors indicated for use in combination for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Limitations of Use: BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma.